BTIG raised the firm's price target on Acumen to $8 from $7 and keeps a Buy rating on the shares. Recent updates suggest multiple TfR-binding scaffolds may meaningfully enhance central nervous system delivery without causing anemia, the analyst tells investors in a research note. Its next candidate, building on lessons from IZCARGO, appears designed to retain Sabirnetug's high selectivity for toxic A-beta oligomers over plaque and monomers, potentially enabling strong efficacy with reduced ARIA risk and a best-in-class safety profile, the firm says.
